HC Wainwright & Co. Reiterates Buy on ALX Oncology Holdings, Maintains $25 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating on ALX Oncology Holdings (NASDAQ:ALXO) and maintained a $25 price target, as stated by analyst Swayampakula Ramakanth.
August 13, 2024 | 11:19 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating on ALX Oncology Holdings (NASDAQ:ALXO) and maintained a $25 price target, indicating continued confidence in the company's prospects.
The reiteration of a Buy rating and maintenance of a $25 price target by a reputable analyst firm like HC Wainwright & Co. is likely to positively influence investor sentiment and support the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100